• News
  • Finance

Providing IR consulting for the biotech industry

Related Special Reports

Stern Investor Relations represents prominent public, private and pre-IPO companies in all stages of development and has represented more than 200 biotechnology, specialty pharmaceuticals, devices, health care services and industrial biotechnology companies over the last 16 years.

Our specific focus on these industries allows us to possess and utilize extensive, detailed and up-to-the-minute knowledge of these niche sectors, including regulatory issues and the current market environment. Based in New York City, we offer a broad range of strategic investor relations services that includes working with senior management to achieve key investor relations goals, such as effective positioning, enhancing visibility, improving institutional ownership and sell-side coverage, preparing for financings and IPOs, developing good guidance practices and managing communications around M&A, binary events and other strategic issues.

Our goal is to help each client realize a valuation that best reflects the company's assets and the internal value of the company through favorable interactions with the investment community. We are deeply committed to each client’s success and maintaining a collaborative working relationship.

The financial markets and the health care and biotechnology industries in particular undergo frequent changes, and Stern IR recognizes the importance of routinely re-evaluating each client's IR program periodically to achieve the greatest return on its investment. As a result of our industry specialization, we have cultivated many valuable relationships within the investment community and know the major players and industry events. We facilitate introductions with crucial contacts on Wall Street and help our clients develop and improve existing relationships. Through a combination of meetings and roadshows, we familiarize the financial community with our clients and their corporate messages.

While each client will have their own set of specific goals and subsequent tactics, we believe that high-quality companies should operate their investor relations management programs according to current best industry practice. We advise our clients accordingly, helping them convey news and information to research analysts and investors regularly and consistently, with special attention to timing, positioning, accuracy and fair disclosure policies. In addition, we provide appropriate guidance to clients to ensure they maintain the credibility that is vital to a company's reputation on Wall Street.

For more information, visit sternir.com.

-Submitted by Stern Investor Relations.

User Response
0 UserComments